TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01370967

Intervention type: OTHER
Intervention: Study formula feeding
Description: Infants who are exclusively fed the new study formula at time of enrollment

Intervention type: OTHER
Intervention: Human milk feeding
Description: Infants who are exclusively fed human milk at time of enrollment

Intervention type: OTHER
Intervention: Mixed feeding
Description: Infants who are exclusively fed human milk and the new study formula at time of enrollment
Study: NCT00288574

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluoxetine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02078219

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RDEA3170
Description: Oral Treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RDEA3170
Description: Oral Treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RDEA3170
Description: Oral Treatment

Intervention type: DRUG
Group type: OTHER
Intervention: Allopurinol
Description: Oral Treatment

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral Treatment
Study: NCT03036527

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Activity-based locomotor training
Description: The weight-bearing activity-based intervention will be provided via a standardized locomotor training program that is provided clinically at Frazier Rehab Institute within the NeuroRecovery Network (NRN); or similar interventions in a research protocol of stepping (IRB 07.0066).

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Activity-based locomotor training
Description: The weight-bearing activity-based intervention will be provided via a standardized locomotor training program that is provided clinically at Frazier Rehab Institute within the NeuroRecovery Network (NRN); or similar interventions in a research protocol of stepping (IRB 07.0066).

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Activity-based stand training
Description: The weight-bearing activity-based intervention will be provided via a standardized locomotor training program that is provided clinically at Frazier Rehab Institute within the NeuroRecovery Network (NRN); or similar interventions in a research protocol of stand only program (07.0268). The stand only intervention may also be provided as part of this study.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Activity-based stand training
Description: The weight-bearing activity-based intervention will be provided via a standardized locomotor training program that is provided clinically at Frazier Rehab Institute within the NeuroRecovery Network (NRN); or similar interventions in a research protocol of stand only program (07.0268). The stand only intervention may also be provided as part of this study.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Activity-based upper arm ergometry
Description: The non-weight bearing activity-based upper arm ergometry intervention will be provided via a standardized arm crank therapy provided within this study.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Activity-based training + spinal epidural stimulation
Description: combination effect of both locomotor training and/or stand training with epidural stimulation targeting locomotion and/or stand.
Study: NCT01526421

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: monetary reinforcer
Description: Participants randomized to the reinforcer arm will receive gift cards at the completion of screening procedures.
Study: NCT01891071

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lung volume recruitment
Description: Inflation of the lungs to their maximal insufflation capacity by the consecutive delivery, by a manual resuscitator in this study, of volumes of air that are held with a closed glottis
Study: NCT02796105

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Progevera

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Orgalutran
Study: NCT03341676

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone 3.3 mg/mL solution for injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sodium Chloride 0.9% w/v solution for injection
Study: NCT00046228

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: abciximab placebo; reteplase placebo, abciximab, abciximab
Description: placebo bolus; 1-2 placebo bolus; 0.25 mg/kg bolus; 0.125 ¼g/kg/min, max 10 ¼g/min infusion x 12h

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abciximab; reteplase; abciximab placebo; abciximab
Description: 0.25 mg/kg bolus; 1-2, 5 unit boluses; placebo bolus; 0.125 ¼g/kg/min, max 10 ¼g/min infusion x 12h

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: abciximab; reteplase placebo; abciximab placebo; abciximab
Description: 0.25 mg/kg bolus; 1-2 placebo boluses; placebo bolus; 0.125 ¼g/kg/min, max 10 ¼g/min infusion x 12h

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: abciximab placebo; reteplase placebo, abciximab, abciximab
Description: placebo bolus; 1-2 placebo bolus; 0.25 mg/kg bolus; 0.125 ¿g/kg/min, max 10 ¿g/min infusion x 12h

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: abciximab; reteplase placebo; abciximab placebo; abciximab
Description: 0.25 mg/kg bolus; 1-2 placebo boluses; placebo bolus; 0.125 ¿g/kg/min, max 10 ¿g/min infusion x 12h

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abciximab; reteplase; abciximab placebo; abciximab
Description: 0.25 mg/kg bolus; 1-2, 5 unit boluses; placebo bolus; 0.125 ¿g/kg/min, max 10 ¿g/min infusion x 12h
Study: NCT01967290

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vibratory feedback and 3D movement analysis
Description: Hand-to-mouth task performed under vibratory feedback combined with 3D continuous movement analysis.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Only 3D movement analysis
Description: Hand-to-mouth task performed under 3D continuous movement analysis only
Study: NCT02254343

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: proximal robot-assisted therapy

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: distal robot-assisted therapy

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: individualized intensive therapy
Study: NCT04181190

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood cell counts
Description: White Blood Cell Count and Differential (and in particular the levels of total leucocytes, lymphocytes, eosinophils and basophils)

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood cell counts
Description: White Blood Cell Count and Differential (and in particular the levels of total leucocytes, lymphocytes, eosinophils and basophils)
Study: NCT05222074

Intervention type: OTHER
Intervention: Venous congestion
Description: Venous congestion exposures were quantified as area under the curve (AUC) of central venous pressure ≥12, 16 or 20 mmHg

Intervention type: OTHER
Intervention: Venous congestion
Description: Venous congestion exposures were quantified as area under the curve (AUC) of central venous pressure ≥12, 16 or 20 mmHg

Intervention type: OTHER
Intervention: Venous congestion
Description: Venous congestion exposures were quantified as area under the curve (AUC) of central venous pressure ≥12, 16 or 20 mmHg

Intervention type: OTHER
Intervention: Introperation hypotension
Description: Introperation hypotension exposures were quantified as area under the curve (AUC) of mean arterial pressure ≤55, 65, 75 mmHg
Study: NCT04181190

Intervention type: DIAGNOSTIC_TEST
Intervention: Asthma control assessment
Description: Levels of asthma control assessed by asthma control questionnaire (ACT) before initiation of biological treatments and at 4± months of treatments

Intervention type: DIAGNOSTIC_TEST
Intervention: Asthma control assessment
Description: Levels of asthma control assessed by asthma control questionnaire (ACT) before initiation of biological treatments and at 4± months of treatments

Intervention type: DIAGNOSTIC_TEST
Intervention: lung function tests
Description: Lung function tests performed before initiation of biological treatments and at 4± months of treatments

Intervention type: DIAGNOSTIC_TEST
Intervention: lung function tests
Description: Lung function tests performed before initiation of biological treatments and at 4± months of treatments
Study: NCT04175379

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: group 40
Description: During surgery, the TV(tidal volume) should maintain 6ml/kg (ideal body weight). After position change and OLV(one lung ventilation) for operation, each patient adjusts RR(respiratory rate) to reach target PaCO2 40 ± 5mmHg. Hemodynamic records and arterial blood tests are performed at the following times: After tracheal intubation, 15 minutes after in two lung ventilatory state at the supine position (T0), after 30 minutes reaching to the target PaCO2 by adjusting RR at the lateral position starting one lung ventilation (T1), and after 60 minutes while maintaining target PaCO2 (T2).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: group 50
Description: During surgery, the TV(tidal volume) should maintain 6ml/kg (ideal body weight). After position change and OLV(one lung ventilation) for operation, each patient adjusts RR(respiratory rate) to reach target PaCO2 50 ± 5mmHg. Hemodynamic records and arterial blood tests are performed at the following times: After tracheal intubation, 15 minutes after in two lung ventilatory state at the supine position (T0), after 30 minutes reaching to the target PaCO2 by adjusting RR at the lateral position starting one lung ventilation (T1), and after 60 minutes while maintaining target PaCO2 (T2).
Study: NCT02113397

Intervention type: DRUG
Intervention: TOBI™ Podhaler™ 112 mg inhaled twice daily
Study: NCT04175379

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: group 60
Description: During surgery, the TV(tidal volume) should maintain 6ml/kg (ideal body weight). After position change and OLV(one lung ventilation) for operation, each patient adjusts RR(respiratory rate) to reach target PaCO2 60 ± 5mmHg. Hemodynamic records and arterial blood tests are performed at the following times: After tracheal intubation, 15 minutes after in two lung ventilatory state at the supine position (T0), after 30 minutes reaching to the target PaCO2 by adjusting RR at the lateral position starting one lung ventilation (T1), and after 60 minutes while maintaining target PaCO2 (T2).
Study: NCT01085045

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PT003 MDI
Description: Inhaled PT003 MDI administered as two puffs BID for 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PT003 MDI
Description: Inhaled PT003 MDI administered as two puffs BID for 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PT005 MDI
Description: Inhaled PT005 MDI administered as two puffs BID for 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PT005 MDI
Description: Inhaled PT005 MDI administered as two puffs BID for 7 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo MDI
Description: Inhaled placebo administered as two puffs BID for 7 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tiotropium bromide 18 μg (Spiriva Handihaler®)
Description: Inhaled tiotropium bromide 18 μg (Spiriva Handihaler®) administered QD for 7 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Formoterol Fumarate 12 μg (Foradil® Aerolizer®)
Description: Inhaled formoterol fumarate 12 μg (Foradil® Aerolizer®) administered BID for 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PT001 MDI
Description: Inhaled PT001 MDI administered as two puffs BID for 7 days
Study: NCT04164745

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib, oral capsule
Description: Participants receive Anlotinib 12 mg p.o, qd on Days 1-14 of each 3-week cycle until progressive disease or unacceptable toxicity plus pembrolizumab 200 mg via intravenous (IV) infusion on Day 1 of each 3-week cycle for up to 35 administrations (up to approximately 2 years).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Participants receive Anlotinib 12 mg p.o, qd on Days 1-14 of each 3-week cycle until progressive disease or unacceptable toxicity plus pembrolizumab 200 mg via intravenous (IV) infusion on Day 1 of each 3-week cycle for up to 35 administrations (up to approximately 2 years).
Study: NCT05222074

Intervention type: OTHER
Intervention: Introperation hypotension
Description: Introperation hypotension exposures were quantified as area under the curve (AUC) of mean arterial pressure ≤55, 65, 75 mmHg
Study: NCT06181006

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pirtobrutinib
Description: Administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pirtobrutinib
Description: Administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pirtobrutinib
Description: Administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pirtobrutinib
Description: Administered orally.
Study: NCT01954264

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Capillary blood sample
Description: Capillary blood sample (up to 200µL) for determination of PP (blood slides).

Intervention type: OTHER
Group type: OTHER
Intervention: Data collection
Description: Prospective data collection at the study visit by the internet based Electronic Case Report Form (eCRF)
Study: NCT02804204

Intervention type: DRUG
Intervention: Anti-TNF
Study: NCT00403039

Intervention type: DRUG
Group type: OTHER
Intervention: Ranibizumab (Lucentis )
Study: NCT03637153

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Assessment at Low Altitude (470m above sea level)
Description: Assessment at Low Altitude (in Zurich; 470m above sea level) in order to compare this data with High altitude exposure

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Assessment at Low Altitude (470m above sea level)
Description: Assessment at Low Altitude (in Zurich; 470m above sea level) in order to compare this data with High altitude exposure

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exposure to High Altitude (2500m above sea level)
Description: Exposure to High Altitude (Säntis; 2500m above sea level) for approximately 5 hours

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exposure to High Altitude (2500m above sea level)
Description: Exposure to High Altitude (Säntis; 2500m above sea level) for approximately 5 hours
Study: NCT01013025

Intervention type: PROCEDURE
Intervention: Ultrasound or CT or MRI to locate implant
Description: Scanning methods (eg, ultrasound, CT, or MRI) were used to locate the implant.
Study: NCT02709278

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: BCG
Description: BCG SSI (Due to a global shortage of BCG SSI, BCG Bulgaria used in Group 2)

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: BCG
Description: BCG SSI (Due to a global shortage of BCG SSI, BCG Bulgaria used in Group 2)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BCG
Description: BCG SSI (Due to a global shortage of BCG SSI, BCG Bulgaria used in Group 2)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BCG
Description: BCG SSI (Due to a global shortage of BCG SSI, BCG Bulgaria used in Group 2)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Saline placebo
Description: Saline placebo

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Saline placebo
Description: Saline placebo

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Saline placebo
Description: Saline placebo

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Saline placebo
Description: Saline placebo

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: BCG
Description: BCG Bulgaria (InterVax)

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: BCG
Description: BCG Bulgaria (InterVax)

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: BCG
Description: BCG Bulgaria (InterVax)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BCG
Description: BCG Bulgaria (InterVax)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BCG
Description: BCG Bulgaria (InterVax)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BCG
Description: BCG Bulgaria (InterVax)
Study: NCT02662790

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Doppler
Study: NCT01572090

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Lifestyle Changes
Description: Hypocaloric diet providing a 1000 kcal/d deficit from total energy expenditure assessed by indirect calorimetry and physical activity determination.~Dietetic and physical activity counselling with a dietitian.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Lifestyle Changes
Description: Hypocaloric diet providing a 1000 kcal/d deficit from total energy expenditure assessed by indirect calorimetry and physical activity determination.~Dietetic and physical activity counselling with a dietitian.
Study: NCT02372630

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Linagliptin
Description: 5 mg daily oral tablets of linagliptin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: matching placebo giving orally daily
Study: NCT02468778

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HeartMate PHP
Description: The HeartMate PHP System is a temporary (\<6 hours) ventricular assist device indicated for use during high-risk percutaneous coronary interventions (PCI) performed electively or urgently in hemodynamically stable patients with severe coronary artery disease, when a heart team, including a cardiac surgeon, has determined high-risk PCI is an acceptable therapeutic option. Use of the HeartMate PHP Systems in these patients may prevent hemodynamic instability, which can result from repeat episodes of reversible myocardial ischemia that occur during planned temporary coronary occlusions and may reduce peri-and post-procedural adverse events.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HeartMate PHP
Description: The HeartMate PHP System is a temporary (\<6 hours) ventricular assist device indicated for use during high-risk percutaneous coronary interventions (PCI) performed electively or urgently in hemodynamically stable patients with severe coronary artery disease, when a heart team, including a cardiac surgeon, has determined high-risk PCI is an acceptable therapeutic option. Use of the HeartMate PHP Systems in these patients may prevent hemodynamic instability, which can result from repeat episodes of reversible myocardial ischemia that occur during planned temporary coronary occlusions and may reduce peri-and post-procedural adverse events.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Any Abiomed Impella® device approved for use in high-risk PCI
Description: Any Abiomed Impella® device approved for use in high-risk PCI.
Study: NCT00234078

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.5% OPC-12759

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1% OPC-12759

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2% OPC-12759

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study: NCT00649753

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Category II Pelvic Blocking
Description: Supine Orthopedic Blocking consists of placing padded wedges underneath the Ilium and greater trochanter to correct pelvic torsion and associated sacroiliac dysfunction.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Category II Pelvic Blocking and Cranial
Description: Supine Orthopedic Blocking consists of placing padded wedges underneath the Ilium and greater trochanter to correct pelvic torsion and associated sacroiliac dysfunction. During pelvic blocking a cranial procedure is performed using a zygomae release and sphenobasilar release. These cranial procedures are manual therapy procedures using light pressure from hand and/or finger contacts.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cranial Only
Description: Without pelvic blocking a cranial procedure is performed using a zygomae release and sphenobasilar release. These cranial procedures are manual therapy procedures using light pressure from hand and/or finger contacts.
Study: NCT01114022

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Experimental 1
Description: oeso pharyngeal device

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Experimental
Description: oeso pharyngeal device

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: experimental 3
Description: oeso pharyngeal device

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active comparator
Description: oeso pharyngeal device
Study: NCT02715622

Intervention type: PROCEDURE
Intervention: Hernia repair
Description: Patient undergoing Hernia repair using different surgical modalities as per the surgeon's standard of care practice

Intervention type: PROCEDURE
Intervention: Hernia repair
Description: Patient undergoing Hernia repair using different surgical modalities as per the surgeon's standard of care practice

Intervention type: PROCEDURE
Intervention: Hernia repair
Description: Patient undergoing Hernia repair using different surgical modalities as per the surgeon's standard of care practice
Study: NCT00921622

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D
Description: 1000 IU twice daily for up to 10 days

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin C
Description: 500 mg twice daily for up to 10 days

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin C
Description: 500 mg twice daily for up to 10 days
Study: NCT04437862

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Q Revascularization System
Description: Q Revascularization System for mechanical thrombectomy
Study: NCT04753710

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ocular gel
Description: Instillation

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ocular gel
Description: Instillation